Acri Capital Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Acri Capital Acquisition (ACAC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Acri Capital Acquisition vs. its Competitors, Q1 2024
Net income growth, year on year
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Acri Capital Acquisition and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Acri Capital Acquisition Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Acri Capital Acquisition's competitor groups requires a Commercial License.
Acri Capital Acquisition's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Acri Capital Acquisition Corp | - | - | - | Yes |
| Competitors combined (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACAC Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Achieve Life Sciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Acri Capital Acquisition's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Acri Capital Acquisition Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Acri Capital Acquisition Corp | - | - |
| Equity Residential | 24,437.67 | 3,030.82 |
| Achieve Life Sciences Inc | 719.10 | - |
| Strategic Acquisitions Inc | 18.34 | 0.08 |
| Avenue Therapeutics Inc | 1.32 | - |
| SUBTOTAL | 25,176.43 | 3,030.90 |
Sources: Acri Capital Acquisition Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Acri Capital Acquisition Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Acri Capital Acquisition's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Strategic Acquisitions Inc | Named by the company | 85% |
| Equity Residential | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Acri Capital Acquisition's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Acri Capital Acquisition's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Acri Capital Acquisition Corp | - | - | 1,840,041 |
| Equity Residential | 24,438 | 1,894,260 | 562,004 |
| Achieve Life Sciences Inc | 719 | - | -4,072,857 |
| Strategic Acquisitions Inc | 18 | 42,456 | -37,956 |
| Avenue Therapeutics Inc | 1 | - | -2,803,000 |
| PEERS TOTAL | 25,176 | 1,858,308 | 479,637 |
Acri Capital Acquisition's Valuation vs Competitive Position
Valuation multiples vs the Blank Checks industry average (68 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Blank Checks industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 27.9x | 45.2x | -17.2x |
| EV / EBITDA | 23.2x | 26.4x | -3.1x |
| P/B | -8.0x | 6.7x | -14.7x |
| Return on Equity | -26.28 % | industry aggregate | -12.16 % |
| Return on Invested Capital | -3.23 % | 0.96 % (avg) | -4.19 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Acri Capital Acquisition's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 12.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 27.5% median pace.
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-3.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Acri Capital Acquisition's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Acri Capital Acquisition Corp | 0.02 | 0.03 | - |
| Equity Residential | 0.08 | 0.08 | 0.42 |
| Achieve Life Sciences Inc | 1.17 | 1.35 | 1.07 |
| Strategic Acquisitions Inc | 5.55 | 7.82 | - |
| Avenue Therapeutics Inc | 2.10 | 2.14 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Acri Capital Acquisition's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Acri Capital Acquisition Corp | Q1 2024 | - | +23,184.7 % |
| Equity Residential | Q2 2026 | -10.7 % | -40.8 % |
| Achieve Life Sciences Inc | Q2 2026 | - | - |
| Strategic Acquisitions Inc | Q2 2026 | - | - |
| Avenue Therapeutics Inc | Q2 2026 | - | - |
| PEERS TOTAL | -10.9 % | -66.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Acri Capital Acquisition's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Acri Capital Acquisition Corp | Q1 2024 | - | - |
| Equity Residential | Q2 2026 | +4.8 % | -80.8 % |
| Achieve Life Sciences Inc | Q2 2026 | - | - |
| Strategic Acquisitions Inc | Q2 2026 | - | - |
| Avenue Therapeutics Inc | Q2 2026 | - | - |
Acri Capital Acquisition's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Acri Capital Acquisition Corp | 67.11% | 75.07% | - |
| Equity Residential | 4.35% | 3.91% | 8.16% |
| Achieve Life Sciences Inc | - | - | - |
| Strategic Acquisitions Inc | - | - | - |
| Avenue Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Acri Capital Acquisition's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Acri Capital Acquisition Corp | 32.37 | - |
| Equity Residential | 27.68 | 8.06 |
| Achieve Life Sciences Inc | - | - |
| Strategic Acquisitions Inc | - | 215.96 |
| Avenue Therapeutics Inc | - | - |
| PEERS AVERAGE | 31.30 | 8.31 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.